Trial Profile
An Adaptive, Open-Label Study to Evaluate the Biodistribution of 89Zirconium-labelled GSK2398852 in the Heart and Other Organs of Patients With Transthyretin Cardiomyopathy (ATTR-CM) Using Positron Emission Tomography (PET) Imaging
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Dezamizumab (Primary) ; Miridesap (Primary) ; Miridesap (Primary)
- Indications Amyloidosis
- Focus Diagnostic use
- Sponsors GlaxoSmithKline; GSK
- 10 Dec 2018 Status changed from suspended to discontinued.
- 20 Aug 2018 Status changed from recruiting to suspended.
- 24 Apr 2018 Planned End Date changed from 18 Dec 2018 to 11 Dec 2018.